603139.SH
康惠股份
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 33.92
−2.75%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 443.3M | 471.3M | 561.6M | 673.0M | 491.5M |
| Cost of Revenue | 321.8M | 351.8M | 388.6M | 483.7M | 292.4M |
| Gross Profit | 121.5M | 119.5M | 173.0M | 189.2M | 199.1M |
| Operating Expenses | |||||
| R&D Expense | 13.5M | 12.2M | 8.3M | 11.0M | 12.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 60.4M | 54.1M | 56.0M | 45.2M | 35.1M |
| Selling & Marketing Expense | 130.0M | 134.6M | 140.3M | 121.7M | 138.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 248.3M | 247.3M | 249.3M | 201.5M | 196.7M |
| Cost and Expenses | 570.1M | 599.1M | 637.9M | 685.2M | 489.0M |
| Operating Income (EBIT) | (292.4M) | (343.5M) | (123.0M) | (61.8M) | (75.7M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (292.5M) | (343.4M) | (121.5M) | (57.9M) | (82.7M) |
| Income Tax Expense | (5.5M) | (7.0M) | (9.5M) | (7.2M) | (6.0M) |
| Bottom Line | |||||
| Net Income | (295.3M) | (333.5M) | (89.6M) | (26.2M) | (63.1M) |
| Earnings from Cont. Ops | (287.0M) | (336.3M) | (112.0M) | (50.8M) | (76.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (295.3M) | (333.5M) | (89.6M) | (26.2M) | (63.1M) |
| Per Share | |||||
| Basic EPS | (CN¥2.96) | (CN¥3.34) | (CN¥0.90) | (CN¥0.26) | (CN¥0.63) |
| Diluted EPS | (CN¥2.96) | (CN¥3.34) | (CN¥0.90) | (CN¥0.26) | (CN¥0.63) |
| Revenue Per Share | CN¥4.46 | CN¥4.72 | CN¥5.64 | CN¥6.69 | CN¥4.91 |
| Shares | |||||
| Basic Shares Outstanding | 99.4M | 99.8M | 99.6M | 100.6M | 100.1M |
| Diluted Shares Outstanding | 99.4M | 99.8M | 99.6M | 100.6M | 100.1M |
| Profitability Metrics | |||||
| EBITDA | — | (276.9M) | (63.0M) | (24.0M) | (49.4M) |
| D&A | — | 66.5M | 60.0M | 37.8M | 26.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026